[
  {
    "ts": null,
    "headline": "Morgan Stanley Reduces PT on Zscaler (ZS) Stock",
    "summary": "Zscaler, Inc. (NASDAQ:ZS) is one of the High Growth Large Cap Stocks to Buy Right Now. On December 18, Morgan Stanley reduced the price target on the company’s stock to $305 from $335, while keeping an “Overweight” rating on the company’s stock. As per the analyst, the cybersecurity stocks remained mainly flat on the year, while […]",
    "url": "https://finnhub.io/api/news?id=6b4fd6568cf41bbca8c8fd9ecd7ba9fa075760f53d7c11b2141da7b99078f7af",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767200222,
      "headline": "Morgan Stanley Reduces PT on Zscaler (ZS) Stock",
      "id": 137950323,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MS",
      "source": "Yahoo",
      "summary": "Zscaler, Inc. (NASDAQ:ZS) is one of the High Growth Large Cap Stocks to Buy Right Now. On December 18, Morgan Stanley reduced the price target on the company’s stock to $305 from $335, while keeping an “Overweight” rating on the company’s stock. As per the analyst, the cybersecurity stocks remained mainly flat on the year, while […]",
      "url": "https://finnhub.io/api/news?id=6b4fd6568cf41bbca8c8fd9ecd7ba9fa075760f53d7c11b2141da7b99078f7af"
    }
  },
  {
    "ts": null,
    "headline": "Morgan Stanley Cautious on SentinelOne (S) Despite AI Growth, Revenue Beat Due to CFO Transition, Enterprise Sales Cycles",
    "summary": "SentinelOne Inc. (NYSE:S) is one of the best low priced technology stocks to buy according to analysts. On December 5, Morgan Stanley lowered the firm’s price target on SentinelOne to $18 from $20 with an Equal Weight rating on the shares. The firm expressed optimism regarding the company’s $3 million revenue beat and the performance […]",
    "url": "https://finnhub.io/api/news?id=0178f8f0ea10db91579803202b8c3a3c9d7db82e9cc7111eed6ce843999faa6c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767198815,
      "headline": "Morgan Stanley Cautious on SentinelOne (S) Despite AI Growth, Revenue Beat Due to CFO Transition, Enterprise Sales Cycles",
      "id": 137950324,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MS",
      "source": "Yahoo",
      "summary": "SentinelOne Inc. (NYSE:S) is one of the best low priced technology stocks to buy according to analysts. On December 5, Morgan Stanley lowered the firm’s price target on SentinelOne to $18 from $20 with an Equal Weight rating on the shares. The firm expressed optimism regarding the company’s $3 million revenue beat and the performance […]",
      "url": "https://finnhub.io/api/news?id=0178f8f0ea10db91579803202b8c3a3c9d7db82e9cc7111eed6ce843999faa6c"
    }
  },
  {
    "ts": null,
    "headline": "Morgan Stanley Expects Gilead Sciences (GILD) to Thrive as Biopharma Policy Uncertainties Fade in 2026",
    "summary": "Gilead Sciences Inc. (NASDAQ:GILD) is one of the best stocks for the next decade. On December 12, Morgan Stanley raised the firm’s price target on Gilead to $151 from $147 with an Overweight rating on the shares. The firm informed investors that the regulatory and political uncertainties currently weighing on biopharma are expected to subside. […]",
    "url": "https://finnhub.io/api/news?id=7ac3153e11a8e04259de50cbae5326875f7e5e9735c705dcdd847fe0b437b09e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767198328,
      "headline": "Morgan Stanley Expects Gilead Sciences (GILD) to Thrive as Biopharma Policy Uncertainties Fade in 2026",
      "id": 137950326,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MS",
      "source": "Yahoo",
      "summary": "Gilead Sciences Inc. (NASDAQ:GILD) is one of the best stocks for the next decade. On December 12, Morgan Stanley raised the firm’s price target on Gilead to $151 from $147 with an Overweight rating on the shares. The firm informed investors that the regulatory and political uncertainties currently weighing on biopharma are expected to subside. […]",
      "url": "https://finnhub.io/api/news?id=7ac3153e11a8e04259de50cbae5326875f7e5e9735c705dcdd847fe0b437b09e"
    }
  },
  {
    "ts": null,
    "headline": "AI Will Demolish 200,000 Jobs According to Expert",
    "summary": "Morgan Stanley forecasts that artificial intelligence will eliminate 200,000 banking jobs in Europe by 2030. Other forecasts are even worse.",
    "url": "https://finnhub.io/api/news?id=aa2b9a0b2a2731567b782f1052d2c10bc8615a9f604c24860963416ef2b6fede",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767190534,
      "headline": "AI Will Demolish 200,000 Jobs According to Expert",
      "id": 137950327,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MS",
      "source": "Yahoo",
      "summary": "Morgan Stanley forecasts that artificial intelligence will eliminate 200,000 banking jobs in Europe by 2030. Other forecasts are even worse.",
      "url": "https://finnhub.io/api/news?id=aa2b9a0b2a2731567b782f1052d2c10bc8615a9f604c24860963416ef2b6fede"
    }
  },
  {
    "ts": null,
    "headline": "AI forecast to put 200,000 European banking jobs at risk by 2030",
    "summary": "More than 200,000 European banking jobs are under threat over the next five years as lenders increasingly embrace artificial intelligence and...",
    "url": "https://finnhub.io/api/news?id=2bca34c2b3cce04cc11a6f475ef871eea43542679d90f0578b2b2aab2eb45574",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767157209,
      "headline": "AI forecast to put 200,000 European banking jobs at risk by 2030",
      "id": 137950328,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MS",
      "source": "Yahoo",
      "summary": "More than 200,000 European banking jobs are under threat over the next five years as lenders increasingly embrace artificial intelligence and...",
      "url": "https://finnhub.io/api/news?id=2bca34c2b3cce04cc11a6f475ef871eea43542679d90f0578b2b2aab2eb45574"
    }
  },
  {
    "ts": null,
    "headline": "Morgan Stanley Initiates Coverage Of Veracyte, Inc. (VCYT)",
    "summary": "Veracyte, Inc. (NASDAQ:VCYT) is among the 12 Best Genomics Stocks to Invest In. The Fly reported on December 2, 2025, that Morgan Stanley began covering Veracyte, Inc. (NASDAQ:VCYT) with an Underweight rating and a price target of $48, up from $40. According to the firm, the Life Science Tools and Diagnostics end markets are showing […]",
    "url": "https://finnhub.io/api/news?id=780401d67ea0f36a9e818f714708dd51948ddec4fe0e0e508f1506afd98d68af",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767156500,
      "headline": "Morgan Stanley Initiates Coverage Of Veracyte, Inc. (VCYT)",
      "id": 137950329,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MS",
      "source": "Yahoo",
      "summary": "Veracyte, Inc. (NASDAQ:VCYT) is among the 12 Best Genomics Stocks to Invest In. The Fly reported on December 2, 2025, that Morgan Stanley began covering Veracyte, Inc. (NASDAQ:VCYT) with an Underweight rating and a price target of $48, up from $40. According to the firm, the Life Science Tools and Diagnostics end markets are showing […]",
      "url": "https://finnhub.io/api/news?id=780401d67ea0f36a9e818f714708dd51948ddec4fe0e0e508f1506afd98d68af"
    }
  }
]